Development and characterization of cellular biosensors for HTS of erythroid differentiation inducers targeting the transcriptional activity of γ-globin and β-globin gene promoters
- 30 Downloads
There is a general agreement that pharmacologically mediated stimulation of human γ-globin gene expression and increase of production of fetal hemoglobin (HbF) is a potential therapeutic approach in the experimental therapy of β-thalassemia and sickle cell anemia. Here, we report the development and characterization of cellular biosensors carrying enhanced green fluorescence protein (EGFP) and red fluorescence protein (RFP) genes under the control of the human γ-globin and β-globin gene promoters, respectively; these dual-reporter cell lines are suitable to identify the induction ability of screened compounds on the transcription in erythroid cells of γ-globin and β-globin genes by FACS with efficiency and reproducibility. Our experimental system allows to identify (a) HbF inducers stimulating to different extent the activity of the γ-globin gene promoter and (b) molecules that stimulate also the activity of the β-globin gene promoter. A good correlation does exist between the results obtained by using the EGFP/RFP clones and experiments performed on erythroid precursor cells from β-thalassemic patients, confirming that this experimental system can be employed for high-throughput screening (HTS) analysis. Finally, we have demonstrated that this dual-reporter cell line can be used for HTS in 384-well plate, in order to identify novel HbF inducers for the therapy of β-thalassemia and sickle cell anemia.
KeywordsHbF inducers Thalassemia Reporter systems HTS Erythroid differentiation Sickle cell anemia
Sickle cell anemia
Erythroid precursor cell
Green fluorescence protein
Enhanced green fluorescence protein
Red fluorescence protein
Locus control region
Fluorescence activated cell sorting
Polymerase chain reaction
Roberto Gambari is funded by Fondazione Cariparo (Cassa di Risparmio di Padova e Rovigo), CIB (Consorzio Interuniversitario per le Biotecnologie), UE THALAMOSS Project (Thalassemia Modular Stratification System for Personalized Therapy of Β-Thalassemia; n. 306201-FP7-HEALTH-2012-INNOVATION-1), by Wellcome Trust (Innovator Award 208872/Z/17/Z) and by AIFA (AIFA-2016-02364887). This research activity was also supported by Associazione Veneta per la Lotta alla Talassemia (AVLT), Rovigo.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
The β-thalassemia patients have been recruited at Thalassemic Day Hospital (DHT) of the University Hospital “Sant’Anna” (Ferrara, Italy). The approval of the collection and processing of the human biological samples for this research was carried out by the Ethics Committee of Ferrara District, number 06/2013 (approved on June 20, 2013). The study complies with the Declaration of Helsinki, the principles of Good Clinical Practice, and all further applicable regulations in accordance with the ethical standards. All samples of peripheral blood have been obtained after written documentation of informed consent from patient or legal representative. Copies of the consents have been collected for archiving by Thalassemic Day Hospital (DHT) of the University Hospital “Sant’Anna” (Ferrara, Italy).
- 2.Gambari R. Foetal hemoglobin inducers and thalassemia: novel achievements. Blood Transfus. 2009;8:5–7.Google Scholar
- 4.Fard AD, Hosseini SA, Shahjahani M, Salari F, Jaseb K. Evaluation of novel fetal hemoglobin inducer drugs in treatment of β-hemoglobinopathy disorders. Int J Hematol Oncol Stem Cell Res. 2013;7:47–54.Google Scholar
- 5.Fibach E, Burke LP, Schechter AN, Noguchi CT, Rodgers GP. Hydroxyurea increases fetal hemoglobin in cultured erythroid cells derived from normal individuals and patients with cell anemia or β-thalassemia. Blood. 1993;81:1630–5.Google Scholar
- 13.Lozzio CB, Lozzio BB. Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome. Blood. 1975;45:321–34.Google Scholar
- 14.Voss JW, Caron C. Inducers of gamma globin gene expression and screening assays therefor. United States Patent 5700640, 1997.Google Scholar
- 16.Skarpidi E, Vassilopoulos G, Li Q, Stamatoyannopoulos G. Novel in vitro assay for the detection of pharmacologic inducers of fetal hemoglobin. Blood. 2000;96:321–6.Google Scholar
- 25.Di Baldassarre A, Di Rico M, Di Noia A, Bonfini T, Iacone A, Marchisio M, et al. Protein kinase Calpha is differentially activated during neonatal and adult erythropoiesis and favors expression of a reporter gene under the control of the (A)gamma globin-promoter in cellular models of hemoglobin switching. J Cell Biochem. 2007;101:411–24.CrossRefGoogle Scholar
- 26.Breveglieri G, Salvatori F, Finotti A, Bertuzzi I, Destro F, Falzoni S, et al. Cellular biosensors for the identification of fetal hemoglobin inducers. Minerva Biotec. 2007;19:123–32.Google Scholar
- 38.Perrine SP, Miller BA, Faller DV, Cohen RA, Vichinsky EP, Hurst D, et al. Sodium butyrate enhances fetal globin gene expression in erythroid progenitors of patients with Hb SS and beta thalassemia. Blood. 1989;74:454–9.Google Scholar